iBio, Inc. (IBIO) Stock

iBio, Inc. (IBIO) is a Healthcare stock trading at $1.44 (as of 2026-08-21), with a market capitalization of $71.54M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

iBio, Inc. is a biotechnology company that provides contract development and manufacturing services for collaborators and third-party customers in the United States, operating across biopharmaceuticals and bioprocessing. It also develops vaccine and therapeutic candidates and manufactures recombinant proteins, along with offering process development, manufacturing, filling/finishing, and bioanalytical services.

Understand iBio, Inc.: how it makes money

iBio, Inc. provides contract development and manufacturing services to biopharma collaborators and third-party customers in the United States, and it also advances its own therapeutic and vaccine candidates.

Because iBio earns from contract development and manufacturing services, its profit model depends on securing collaborator and third-party work and delivering those service projects, not on selling a finished commercial product.

Business quality (Weak): Clear business model (contract development and manufacturing plus an early pipeline), but the provided data does not include reportable segment revenue breakdowns, and the latest quarter shows revenue at 0.0B with a deeply negative operating margin.

Bull case

Contract development and manufacturing platform: iBio provides contract development and manufacturing services to collaborators and third-party customers, which can create demand for its capabilities beyond its own candidates.
Pipeline advancement for multiple indications: Its lead therapeutic candidate, IBIO-100, is being advanced for investigational new drug development for systemic scleroderma and idiopathic pulmonary fibrosis.
Preclinical IBIO-610 fat-reduction signals: Preclinical metrics provided for IBIO-610 include results such as visceral fat reduction and overall weight reduction in combination therapy.

Bear case

Very weak profitability in the latest quarter shown: For 2026-03-31, operating margin is -1273.2 and revenue is shown as 0.0B in the provided data.
Service economics are not demonstrated here with segment detail: The provided facts do not include reportable segment revenue amounts for Biopharmaceuticals versus Bioprocessing, limiting visibility into what is driving results.
Many performance metrics provided are preclinical: The operating metrics given relate to preclinical IBIO-610 outcomes, which may not translate into clinical success or future commercial revenue.

Valuation — source: SEC EDGAR (first-party)
Price	$1.44
Market Cap	$71.54M
Price / Book	0.92
Price / Sales	94.50
FCF Yield	-63.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$400000.00
Net Margin	-4594.3%
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	-81.3%
FCF Growth (YoY)	51.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	-20.46 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.0

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Affinity Asset Advisors, LLC ($5.90M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Martin Brenner
Employees	16
Country	US
IPO Date	2008-08-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.